← Leaderboards
Muhammed Murtaza
Translational Genomics Research Inst
$5,522,566
Attributed
$6,740,773
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,740,773 · 5
By mechanism
U01$3,756,119 · 2
R01$1,978,528 · 1
UH3$696,635 · 1
UH2$309,491 · 1
Top collaborators
- Javeed Iqbal5 shared
- Wing C. Chan4 shared
- Joo Song1 shared
Others in their field
Other Emerging Leaders on “Sampling”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,167,581
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Scott Topper · Broad Institute, Inc.$77,958,806
- Paul F Gallagher · Woods Hole Oceanographic Institution$63,916,876
- Leonard Freedman · Leidos Biomedical Research, Inc.$60,323,945
- Dale Sandler · Social And Scientific Systems, Inc.$59,740,435
Research focus
SamplingTumorMolecularProspectivePlasmaMutationTumor DnaGenotypeAffectDetectionSomatic MutationMonitorDigitalDiagnosticDisease ProgressionTissuesMalignant NeoplasmsEnrollmentClinical TrialsImproved OutcomeBiopsyMalignant Breast NeoplasmBlood SpecimenDna Analysis
Grant awards (19)
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$367,321
U01 · FY2025 · CA
Treatment monitoring in early and locally advanced breast cancer using circulating tumor DNA analysis$354,931
UH3 · FY2025 · CA · contact PI
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$348,939
U01 · FY2024 · CA
Treatment monitoring in early and locally advanced breast cancer using circulating tumor DNA analysis$341,704
UH3 · FY2024 · CA · contact PI
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$359,942
U01 · FY2023 · CA
Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer$349,281
U01 · FY2023 · CA · contact PI
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$359,962
U01 · FY2022 · CA
Individualized monitoring of treatment response and resistance in patients with metastatic melanoma$351,300
R01 · FY2022 · CA · contact PI
Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer$349,281
U01 · FY2022 · CA · contact PI
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$391,146
U01 · FY2021 · CA
Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer$371,103
U01 · FY2021 · CA · contact PI
Individualized monitoring of treatment response and resistance in patients with metastatic melanoma$351,300
R01 · FY2021 · CA · contact PI
Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer$419,136
U01 · FY2020 · CA · contact PI
Individualized monitoring of treatment response and resistance in patients with metastatic melanoma$415,333
R01 · FY2020 · CA · contact PI
Treatment monitoring in early and locally advanced breast cancer using circulating tumor DNA analysis$206,918
UH2 · FY2020 · CA · contact PI
Treatment monitoring in early and locally advanced breast cancer using circulating tumor DNA analysis$102,573
UH2 · FY2020 · CA · contact PI
Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer$440,008
U01 · FY2019 · CA · contact PI
Individualized monitoring of treatment response and resistance in patients with metastatic melanoma$402,872
R01 · FY2019 · CA · contact PI
Individualized monitoring of treatment response and resistance in patients with metastatic melanoma$457,723
R01 · FY2018 · CA · contact PI